12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Deals

Inspiration Biopharmaceuticals, Ipsen deal

Ipsen said it would not be required to pay $12.5 million for equity in Inspiration under terms of an August restructuring of a 2010 hemophilia deal. As a part of the restructuring, Ipsen would have been required to acquire the equity if Inspiration raised third-party financing by Sept....

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >